Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (24449)	8/13/1998 3:20:00 PM
From: Mudcat	Read Replies (1) \| Respond to of 32384

<would you mind explaining why you think that the payment would've been a better value? You did say that it was a huge mistake.> It was a mistake for the following reasons: 1. Lgnd is cash starved and needs all their cash to continue operating. The payment from Lilly would have given Lgnd a nice cushion to operate with. Instead, they wind up diluting their stock even further by issuing more shares plus cash to buy SRGN. 2. ONTAK is a treatment for CTCL. So is Targretin. Correct me if I'm wrong Henry. Why would Lgnd buy another treatment for CTCL when they already are about to get one approved (Targretin) that does not have the side effects of ONTAK and does not have to be taken intravenously. Does Lgnd have doubts about Targretin? If you believe Henry's posts, Targretin appears to be a far superior treatment for CTCL, and would have taken the majority of the sales anyway.